(Q50579768)

15 March 2018

title

Combination of tumour markers CEA and CA19-9 improves the prognostic prediction in patients with pancreatic cancer. (English)

1 reference

15 March 2018

Daniel Reitz

1

0 references

author name string

Armin Gerger

2

1 reference

15 March 2018

Julia Seidel

3

1 reference

15 March 2018

Peter Kornprat

4

1 reference

15 March 2018

Hellmut Samonigg

5

1 reference

15 March 2018

Michael Stotz

6

1 reference

15 March 2018

Joanna Szkandera

7

1 reference

15 March 2018

Martin Pichler

8

1 reference

15 March 2018

language of work or name

English

0 references

publication date

10 March 2015

1 reference

15 March 2018

Journal of Clinical Pathology

published in

1 reference

15 March 2018

volume

68

1 reference

15 March 2018

issue

6

1 reference

15 March 2018

page(s)

427-433

1 reference

15 March 2018

Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010.

cites work

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202451

21 January 2018

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202451

Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202451

Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202451

The clinical utility of biomarkers in the management of pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202451

Biomarkers for pancreatic cancer: promising new markers and options beyond CA 19-9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202451

Serum CA 19-9 and CEA levels as a prognostic factor in pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202451

CEA and CA-19.9 serum tumor markers as prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202451

Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202451

Biomarkers in pancreatic cancer: diagnostic, prognostic, and predictive.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202451

Clinico-pathological characteristics and clinical outcome of different histological types of pancreatic cancer in a large Middle European series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202451

Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202451

Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202451

CA 19-9 and survival in advanced and unresectable pancreatic adenocarcinoma and cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202451

CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202451

Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202451

Serum CA 19-9 as a Biomarker for Pancreatic Cancer-A Comprehensive Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202451

The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202451

Serum HCG beta and CA 72-4 are stronger prognostic factors than CEA, CA 19-9 and CA 242 in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2014-202451

10.1136/JCLINPATH-2014-202451

21 January 2018

Identifiers

DOI

1 reference

15 March 2018

1 reference

15 March 2018